Stopping myeloma before it even gets started! Lot of work is being done in this preventative approach and Dr. Irene Ghobrial of Dana Farber Cancer Institute will be talking to us about the new strategies to help MGUS and smoldering patients. In contrast to the watch and wait approach practised by doctors for patients where disease progression is not easily discernable, this new approach to understand the patients condition and treat early may prove to be life saving.
Dr. Ghobrial is an Associate Professor of Medicine at Dana-Farber Cancer Institute at the Harvard Medical School in Boston, Massachusetts. She is a physician Scientist who specializes in the field of Multiple Myeloma and Waldenstrom Macroglobulinemia specifically in the precursor conditions of MGUS and Smoldering Myeloma.She reviews abstracts for the American Association of Cancer Research and top publications such as Blood, Lancet, and the Journal of Clinical Oncology just to name a few. She’s on the editorial board of the American Journal of Blood Research. Dr. Ghobrial reviews grants for the NIH, the Leukemia & Lymphoma Society and the MMRF and has won numerous awards including a Dana-Farber Clinical Investigator Award, the Robert Kyle Award for her work in Waldenstrom and the American Society of Clinical Investigation. She particularly focuses on the role of the malignant bone marrow niche in disease progression from early precursor conditions like MGUS/smoldering myeloma to active myeloma.
Sorry we couldn't complete your registration. Please try again.
You must accept the Terms and conditions to register